Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: A proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 5, 2013, Pages 609-616

  Lee, K Y ^a   Jeon, S Y ^a   Hong, J W ^a   Choi, K W ^a   Lee, C Y ^a   Choi, S J ^b,d   Kim, J H ^c   Song, K H ^a   Kim, K H ^a  

^a Dong A University   (South Korea)

^b Daeduk University   (South Korea)

^c Skin Med Co   (South Korea)

^d Chonbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR II; ENDOTHELIN 1; GELATINASE A; GELATINASE B; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MONOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VITILIGO;

CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIN-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOCYTES; PHOTOTHERAPY; RECEPTORS, CXCR; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO;

EID: 84876134283     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04498.x     Document Type: Article

References (32)

1. Gauthier Y, Cario AM, Taïeb A,. A critical appraisal of vitiligo etiologic theories, is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-332.
2. Castanet J, Ortonne JP,. Pathophysiology of vitiligo. Clin Dermatol 1997; 15: 845-851.
3. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
4. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo; imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92.
5. Kang HY, Choi YM,. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 2006; 155: 1037-1040.
6. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
7. Skaehill PA,. Tacrolimus in dermatologic disorders. Ann Pharmacother 2001; 35: 582-588.
8. Fai D, Cassano N, Vena GA,. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 2007; 21: 916-920.
9. Funasaka Y, Chakraborty AK, Hayashi Y, et al. Modulation of melanocyte-stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin-1alpha, interleukin-1beta, endothelin-1 and tumour necrosis factor-alpha. Br J Dermatol 1998; 139: 216-224.
10. Kadekaro AL, Kavanagh R, Kanto H, et al. Alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005; 65: 4292-4299.
11. Zhu N, Lalla R, Eves P, et al. Melanoma cell migration is upregulated by tumour necrosis factor-alpha and suppressed by alpha-melanocyte-stimulating hormone. Br J Cancer 2004; 90: 1457-1463.
12. Imokawa G, Yada Y, Miyagishi M,. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992; 267: 24675-24680.
13. Yada Y, Higuchi K, Imokawa G,. Effects of endothelins on signal transduction and proliferation in human melanocytes. J Biol Chem 1991; 266: 18352-18357.
14. Hara M, Yaar M, Gilchrest BA,. Endothelin-1 of keratinocyte origin is a mediator of melanocyte dendricity. J Invest Dermatol 1995; 105: 744-748.
15. Yohn JJ, Morelli JG, Walchak SJ, et al. Cultured human keratinocytes synthesize and secrete endothelin-1. J Invest Dermatol 1993; 100: 23-26.
16. Tada A, Suzuki I, Im S, et al. Endothelin-1 is a paracrine growth factor that modulates melanogenesis of human melanocytes and participates in their responses to ultraviolet radiation. Cell Growth Differ 1998; 9: 575-584.
17. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J 2006; 20: 1561-1563.
18. Kim HJ, Sung HC, Park KD, et al. The effects of tacrolimus on keratinocytes and melanocytes of vitiligo. Korean J Dermatol 2006; 44: 708-713.
19. Kulke R, Bornscheuer E, Schlüter C, et al. The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 1998; 110: 90-94.
20. Lee J, Horuk R, Rice GC, et al. Wood WI, characterization of two high affinity human interleukin-8 receptors. J Biol Chem 1992; 267: 16283-16287.
21. Norgauer J, Dichmann S, Peters F, et al. Tumor necrosis factor alpha induces upregulation of CXC-chemokine receptor type II expression and magnifies the proliferative activity of CXC-chemokines in human melanocytes. Eur J Dermatol 2003; 13: 124-129.
22. Lan CC, Wu CS, Chen GS, et al. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. Br J Dermatol 2011; 164: 490-496.
23. Hofmann UB, Westphal JR, Van Muijen GN, et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115: 337-344.
24. Bode W, Fernandez-Catalan C, Tschesche H, et al. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639-652.
25. Nagase H, Woessner JF Jr,. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
26. Kaehaeri VM, Saarialho-Kere U,. Matrix metalloproteinases and their inhibitors on tumour growth. Ann Med 1999; 31: 34-45.
27. Hofmann UB, Westphal JR, Waas ET, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2(MMP-2) correlates with melanoma progression. Br J Cancer 1999; 81: 774-782.
28. MacDougall JR, Bani MR, Lin Y, et al. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995; 55: 4174-4181.
29. Väisänen A, Kallioinen M, Taskinen PJ, et al. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51-58.
30. Lee JS, Choi YM, Kang HY,. PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes. Exp Dermatol 2007; 16: 118-123.
31. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.
32. Meier F, Caroli U, Satyamoorthy K, et al. Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol 2003; 12: 296-306.